Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
Clene(CLNN) Newsfilter·2024-05-08 20:00
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) Peer-reviewed publication characterized the protein corona of CNM-Au8 Company received sub-award of 27.9 million as of March 31, 2024 SALT LAKE CITY, May 08, 2024 (GLOBE NEWSWIR ...